In a report released on February 15, Mani Foroohar from SVB Securities reiterated a Buy rating on AlloVir (ALVR – Research Report), with a price target of $16.00. The company’s shares opened today at $6.18.
According to TipRanks, Foroohar is an analyst with an average return of -9.8% and a 44.69% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Bluebird Bio, Rocket Pharmaceuticals, and Editas Medicine.
AlloVir has an analyst consensus of Moderate Buy, with a price target consensus of $18.00, implying a 191.26% upside from current levels. In a report released on February 15, Morgan Stanley also maintained a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $10.29 and a one-year low of $3.17. Currently, AlloVir has an average volume of 248.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm’s pipeline includes ALVR106, ALVR109, ALVR108, and others. The company’s product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Read More on ALVR:
